We're here for you if you want to talk?

0808 2080 888

[email protected]

TORCH trial

Some types of DLBCL don’t respond to standard treatment and this can mean some people see their disease return. In this trial, researchers are studying a new drug to see whether it could be used to treat these people.

The context

People with diffuse B cell lymphoma (DLBCL) – a type of non-Hodgkin lymphoma – are usually treated with chemotherapy and another therapy called rituximab. Although this treatment is successful for many people, sometimes the treatment isn’t effective, and people can see their disease return.

The project

This trial is looking at a whether a drug called vistusertib could benefit people with DLBCL whose cancer has stopped responding to standard treatment. Vistusertib is a type of therapy that prevents cancer cells from growing by blocking the signals that cancer cells use to divide and grow. Rituximab is a type of therapy called a monoclonal antibody. It works by targeting a protein called CD20, which is found on the surface of blood cells. The antibody attaches to these cells, which triggers a response and causes the immune system to come attack and destroy these cells. Rituximab causes both healthy and cancerous white blood cells to be destroyed, but the body can replenish the healthy white blood cells once the treatment is over. Researchers want to know if vistersertib is effective and safe to give people who have seen their DLBCL return. They also want to know if giving rituximab alongside vistusertib provides any additional benefit, so will be testing this drug combination in a small number of people.

The aims

  • Find out If vistusertib helps people with DLBCL
  • Find out if combining vistusertib with rituximab is a useful and safe treatment
  • Learn more about the side effects of the combination therapy